⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of Neuhyll Therapeutics, Inc. and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Neuhyll Therapeutics, Inc.
↗Newbury Park, USA
Neuhyll Therapeutics is an emerging, private biotechnology company focused on the research and development of innovative pharmaceutical therapies. The company maintains operations in the United States, with a registered address in Newbury Park, California, and has established international subsidiaries, such as Lingrui (Hangzhou) Life Sciences Co., Ltd. in China.
The company is actively engaged in clinical development, with active trials for candidates such as NHL907. Neuhyll has attracted investment from prominent venture capital firms, including Qiming Ventures, which led its Series A financing round.
CLASSIFICATION
Company Type:Biotech
Therapeutic Areas:-
Industry:Biotechnology
Sub-Industry:Drug Discovery and Development
SIZE & FINANCIALS
Employees:1-50
Ownership:private
Status:operating
FUNDING
Stage:Series A
Investors:Qiming Ventures
PIPELINE
Stage:Phase 1
Lead Drug Stage:Phase 1
Active Trials:1
Trial Phases:Phase 1: 1
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Subsidiaries:Lingrui (Hangzhou) Life Sciences Co., Ltd., NeuHyll AUS Pty Ltd
COMPETITION
Position:Emerging
LEADERSHIP
Key Executives:
Xu Cen - Director/Manager
LINKS
Website:neuhyll.com
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Neuhyll Therapeutics, Inc.. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.